SCHEMBL5991985

SCHEMBL5991985

C#Cc1ccc(Nc2cc(F)ccc2C(=O)NOCCO)c(C)c1

nearest known ligand 0.62

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 20/20 0.62
MAP2K2 P36507 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6948484 0.86 MAP2K1 (0.64) MAP2K1MAP2K2
SCHEMBL5991182 0.85 MAP2K1 (0.64) MAP2K1MAP2K2
SCHEMBL4857251 0.84 MAP2K1 (0.74) MAP2K1MAP2K2
SCHEMBL5992377 0.81 MAP2K1 (0.62) MAP2K1MAP2K2
SCHEMBL6946571 0.81 CLCN2 (0.51) MAP2K1MAP2K2
SCHEMBL7051635 0.80 MAP2K1 (0.69) MAP2K1MAP2K2
SCHEMBL4856709 0.79 MAP2K1 (0.67) MAP2K1MAP2K2
SCHEMBL24195810 0.78 MAP2K1 (0.81) MAP2K1MAP2K2
SCHEMBL5385905 0.77 MAP2K1 (0.59) MAP2K1MAP2K2
SCHEMBL6229824 0.77 MAP2K1 (0.64) MAP2K1MAP2K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7078438-B2 N-(4 substituted phenyl)-anthranilic acid hydroxamate esters WARNER-LAMBERT COMPANY (US) 2006-07-18 US disclosed
US-20050137263-A1 N-(4 substituted phenyl)-anthranilic acid hydroxamate esters WARNER-LAMBERT COMPANY, LLC 2005-06-23 US disclosed
US-6891066-B2 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters WARNER-LAMBERT COMPANY (US) 2005-05-10 US disclosed
EP-1467968-A1 N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS Warner-Lambert Company LLC (US) 2004-10-20 EP disclosed
US-20040006245-A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters REWCASTLE GORDON WILLIAM (NZ) 2004-01-08 US disclosed
WO-2003062191-A1 N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS WARNER-LAMBERT COMPANY LLC (US) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137263-A1 N-(4 substituted phenyl)-anthranilic acid hydroxamate esters PAH, EGLN3, PAOX MAP2K1 4555/4885MAP2K2 4495/4885
US-20040006245-A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters HCAR2, EGLN3, AADAC MAP2K1 4692/4885MAP2K2 4611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.